Provided by Tiger Trade Technology Pte. Ltd.

Biocryst Pharmaceuticals

9.55
-0.1100-1.14%
Post-market: 9.660.1099+1.15%19:30 EDT
Volume:2.50M
Turnover:24.02M
Market Cap:2.44B
PE:-6.34
High:9.91
Open:9.72
Low:9.48
Close:9.66
52wk High:11.22
52wk Low:6.00
Shares:255.54M
Float Shares:222.00M
Volume Ratio:0.94
T/O Rate:1.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5054
EPS(LYR):1.21
ROE:587.33%
ROA:52.86%
PB:-5.37
PE(LYR):7.89

Loading ...

BioCryst Pharmaceuticals (BCRX) Faces A Valuation Test, Is The Undervalued Case Convincing?

Simply Wall St.
·
Aug 04

Earning Preview: Biocryst Pharmaceuticals Q2 revenue is expected to increase by 21.89%, and institutional views are cautiously optimistic

Earnings Agent
·
Jul 29

Biocryst to Report Q2 2026 Results, Host Conference Call and Webcast

Reuters
·
Jul 22

Biocryst Names David Jenkins Chief Scientific Officer

Reuters
·
Jul 15

Biocryst Appoints David W. Jenkins as Chief Scientific Officer

THOMSON REUTERS
·
Jul 15

BioCryst (BCRX) Receives a Buy from Wedbush

TIPRANKS
·
Jul 13

Biocryst Pharmaceuticals Price Target Announced at $12.00/share by JP Morgan

Dow Jones
·
Jul 13

J.P. Morgan Initiates a Hold Rating on BioCryst (BCRX)

TIPRANKS
·
Jul 13

Is BioCryst (BCRX) Trading Internal Discovery for a More Durable Rare-Disease Innovation Model?

Simply Wall St.
·
Jul 09

Biocryst Pharmaceuticals is Maintained at Outperform by RBC Capital

Dow Jones
·
Jul 07

Eupraxia Pharma Adds Robert Bazemore, Amy Pott, Helen Thackray to Board

Reuters
·
Jul 07

Kioxia Ships Next-gen Memory Samples as AI Boom Fuels Dramatic Comeback

Reuters
·
Jul 03

Biocryst Grants New Hires Stock Options for 33,950 Shares at $9.65 Each

Reuters
·
Jul 02

Biocryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 02

Analysts Are Bullish on Top Healthcare Stocks: BioCryst (BCRX), Zymeworks (ZYME)

TIPRANKS
·
Jun 30

Biocryst Pharmaceuticals is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Jun 30

Cantor Fitzgerald Sticks to Its Buy Rating for BioCryst (BCRX)

TIPRANKS
·
Jun 30

BioCryst to Discontinue Internal Discovery Programs, Close Birmingham Facility by Year-End

MT Newswires Live
·
Jun 29

Biocryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility

THOMSON REUTERS
·
Jun 29

Biocryst Pharmaceuticals - Reaffirms Full Year 2026 Orladeyo and Total Company Revenue Guidance

THOMSON REUTERS
·
Jun 29